Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T R CLARKE

Showing results (71-80 of 119) with videos related to

Pageof 12
Sort By:
Biochimica Et Biophysica Acta|October 24, 2002
Novel mutations (Asn 484 Lys, Thr 500 Ala, Gly 438 Glu) in Morquio B diseaseRichard D Bagshaw, Sunqu Zhang, Alina Hinek, et al.
The Journal of Biological Chemistry|January 24, 2007
Pyrimethamine as a potential pharmacological chaperone for late-onset forms of GM2 gangliosidosisGustavo H B Maegawa, Michael Tropak, Justin Buttner, et al.
American Journal of Medical Genetics. Part A|March 14, 2007
Late onset Leigh syndrome and ataxia due to a T to C mutation at bp 9,185 of mitochondrial DNAAvril E Castagna, Jane Addis, Roderick R McInnes, et al.
Molecular Genetics and Metabolism|February 19, 2014
Outcomes of patients treated through the Canadian Fabry disease initiativeS M Sirrs, D G Bichet, R Casey, et al.
The West Indian Medical Journal|March 2, 2011
Patterns of depressive symptoms among patients with HIV infectionW De La Haye, T R Clarke, G Lipps, et al.
The West Indian Medical Journal|March 2, 2011
HIV seroprevalence among hospital inpatients with neuropsychiatric and other central nervous system disordersR C Gibson, S Jackson, W D Abel, et al.
Biology of Reproduction|September 20, 2000
Human Müllerian-inhibiting substance promoter contains a functional TFII-I-binding initiatorN Morikawa, T R Clarke, C D Novina, et al.
Molecular Genetics and Metabolism|October 8, 2010
An open-label Phase I/II clinical trial of pyrimethamine for the treatment of patients affected with chronic GM2 gangliosidosis (Tay-Sachs or Sandhoff variants)Joe T R Clarke, Don J Mahuran, Swati Sathe, et al.
American Journal of Medical Genetics. Part A|May 15, 2008
Interstitial deletion of 1p22.2p31.1 and medium-chain acyl-CoA dehydrogenase deficiency in a patient with global developmental delayGustavo H B Maegawa, Nicola K Poplawski, Brage Storstein Andresen, et al.
Molecular Genetics and Metabolism|December 22, 2009
Baseline characteristics of patients enrolled in the Canadian Fabry Disease InitiativeS Sirrs, J T R Clarke, D G Bichet, et al.
Pageof 12

Showing results (71-80 of 119) with videos related to

Sort By:
Pageof 12
Biochimica Et Biophysica Acta|October 24, 2002
Novel mutations (Asn 484 Lys, Thr 500 Ala, Gly 438 Glu) in Morquio B diseaseRichard D Bagshaw, Sunqu Zhang, Alina Hinek, et al.
The Journal of Biological Chemistry|January 24, 2007
Pyrimethamine as a potential pharmacological chaperone for late-onset forms of GM2 gangliosidosisGustavo H B Maegawa, Michael Tropak, Justin Buttner, et al.
American Journal of Medical Genetics. Part A|March 14, 2007
Late onset Leigh syndrome and ataxia due to a T to C mutation at bp 9,185 of mitochondrial DNAAvril E Castagna, Jane Addis, Roderick R McInnes, et al.
Molecular Genetics and Metabolism|February 19, 2014
Outcomes of patients treated through the Canadian Fabry disease initiativeS M Sirrs, D G Bichet, R Casey, et al.
The West Indian Medical Journal|March 2, 2011
Patterns of depressive symptoms among patients with HIV infectionW De La Haye, T R Clarke, G Lipps, et al.
The West Indian Medical Journal|March 2, 2011
HIV seroprevalence among hospital inpatients with neuropsychiatric and other central nervous system disordersR C Gibson, S Jackson, W D Abel, et al.
Biology of Reproduction|September 20, 2000
Human Müllerian-inhibiting substance promoter contains a functional TFII-I-binding initiatorN Morikawa, T R Clarke, C D Novina, et al.
Molecular Genetics and Metabolism|October 8, 2010
An open-label Phase I/II clinical trial of pyrimethamine for the treatment of patients affected with chronic GM2 gangliosidosis (Tay-Sachs or Sandhoff variants)Joe T R Clarke, Don J Mahuran, Swati Sathe, et al.
American Journal of Medical Genetics. Part A|May 15, 2008
Interstitial deletion of 1p22.2p31.1 and medium-chain acyl-CoA dehydrogenase deficiency in a patient with global developmental delayGustavo H B Maegawa, Nicola K Poplawski, Brage Storstein Andresen, et al.
Molecular Genetics and Metabolism|December 22, 2009
Baseline characteristics of patients enrolled in the Canadian Fabry Disease InitiativeS Sirrs, J T R Clarke, D G Bichet, et al.
Pageof 12